Relationship between Cytomegalovirus and Hepatic Function Abnormalities in the Period after Renal Transplant

Forty-five consecutive recipients of renal transplants have been studied for three to 18 months (average time, 9.5 months). Sera were collected before transplant and at one, two, three, six, nine, 12, 15, and 18 months and tested for complement fixation antibody against cytomegalovirus (CMV) and her...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 1974-05, Vol.129 (5), p.511-518
Main Authors: Luby, James P., Burnett, William, Hull, Alan R., Ware, Athol J., Shorey, James W., Peters, Paul C.
Format: Article
Language:English
Subjects:
Antibodies
Antibodies, Viral - analysis
Azathioprine - therapeutic use
Blood transfusion
Complement Fixation Tests
Cytomegalovirus
Cytomegalovirus - isolation & purification
Hepatitis
Hepatitis A - microbiology
Hepatitis antigens
Hepatitis B - etiology
Hepatitis B - immunology
Hepatitis B Antibodies - analysis
Hepatitis B Antigens - analysis
Humans
Immunoelectrophoresis
Immunosuppression
Infections
Kidney Transplantation
Liver - physiopathology
Liver function
Major Articles
Radioimmunoassay
Simplexvirus - isolation & purification
Transplantation
Transplantation, Homologous
Viruses
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Forty-five consecutive recipients of renal transplants have been studied for three to 18 months (average time, 9.5 months). Sera were collected before transplant and at one, two, three, six, nine, 12, 15, and 18 months and tested for complement fixation antibody against cytomegalovirus (CMV) and herpes simplex virus type 1 (HSV1 ) . Before transplantation 34.3% had CMV titers ⩾1:4, while the comparable figure for HSV1 was 42.9%. After transplantation 72.7% had fourfold or greater rises in CMV titer, while only 18.2% had such rises to HSVl Twenty of 44 patients (45.4%) developed chemical evidence of hepatitis following transplantation. Nine of the 20 had hepatitis B antigen-positive hepatitis. Nine of the remaining 11 patients had onset of hepatitis when they were undergoing CMV seroconversion. The attack rate of hepatitis B antigen-negative hepatitis was higher in persons who had greater maximal rises in antibody titer to CMV. Thirteen of the 20 cases, including five associated temporally with CMV seroconversion, had evidence of continuing hepatic dysfunction at and beyond 120 days. The study indicates comparability of initial prevalence of antibody to CMV and HSV1 despite transfusion of an average of 7.7 units per person (predominantly leukocyte-poor blood) within three months of transplant. CMV may be an important cause of hepatic function abnormalities after renal transplant, and some of the changes induced may be chronic.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/129.5.511